Alterome Therapeutics Raises $132M in Series B Funding to Advance Cancer Therapies

Alterome Therapeutics' Series B Funding

Key Highlights:

• Series B Funding: Raised $132 million in Series B funding.
• Investors: Led by Goldman Sachs Alternatives, with participation from Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors.
• Pipeline Programs: Funds will be used to advance multiple wholly-owned pipeline programs into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor.

Alterome Therapeutics' Target Market

• Target Market: Precision oncology, focusing on the development of alteration-specific therapeutics for the treatment of cancer.
• Oncology Specialists: Collaboration with oncologists and cancer treatment centers for clinical trials and adoption of Alterome's targeted therapies.
• Pharmaceutical Companies: Potential partnerships with pharmaceutical companies for further development and commercialization of Alterome's pipeline programs.

What Alterome Therapeutics Needs to Buy

• Clinical Research and Development Services: Collaborations with research organizations and clinical trial providers for the advancement of pipeline programs into clinical testing.
• Manufacturing and Supply Chain Solutions: Partnerships with manufacturers and suppliers for the production and distribution of targeted therapies.
• Regulatory and Compliance Expertise: Engagement with regulatory consultants and experts to navigate the complex regulatory landscape in the biopharmaceutical industry.